Compare HYFM & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HYFM | RDHL |
|---|---|---|
| Founded | 1977 | 2009 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0M | 4.2M |
| IPO Year | 2020 | 2012 |
| Metric | HYFM | RDHL |
|---|---|---|
| Price | $1.17 | $0.59 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 3.7M | 33.8K |
| Earning Date | 05-12-2026 | 04-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $134,252,000.00 | N/A |
| Revenue This Year | $57.44 | $381.91 |
| Revenue Next Year | $5.71 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.50 | $0.58 |
| 52 Week High | $4.76 | $2.79 |
| Indicator | HYFM | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 50.10 | 38.14 |
| Support Level | $0.78 | $0.58 |
| Resistance Level | $2.52 | $1.07 |
| Average True Range (ATR) | 0.38 | 0.05 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 27.96 | 14.36 |
Hydrofarm Holdings Group Inc is an independent manufacturer and distributor of branded hydroponics equipment and supplies for controlled environment agriculture (CEA), including grow lights, climate control solutions, grow media, nutrients, and other products. Hydroponics involves growing plants in soilless media, often using artificial lighting in controlled indoor or greenhouse environments. Its products are used to cultivate cannabis, flowers, fruits, vegetables, grains, and herbs, enabling control over key factors such as temperature, humidity, light, nutrients, and pH. Its product portfolio spans lighting, grow media (i.e., premium soils and soil alternatives), nutrients, equipment, and supplies. The United States generates maximum revenue.
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.